Out of 560 AML patients, 116 (20.7%) patients were with FLT3-ITD/TKD mutations, 45 (8.0%) were with NRAS mutations, 59 (10.5%) were with C-KIT mutations, 100 (17.9%) were with NPM1 mutations, 38 (6.8%) were with WT1 mutations, 118 (21.1%) were with CEBPA mutations, 62 (11.1%) were with DNMT3A mutations, 79 (14.1%) were with IDH1/2 mutations, and 27 (4.8%) were with MLL-PTD mutations, respectively. This evidence concerns the gene FLT3 and acute myeloid leukemia.